NICE has recommended Amgen’s multiple myeloma treatment Kyprolis, a next generation drug which has shown itself superior to Janssen’s standard treatment Velcade.
NICE has rejected Janssen’s Darzalex (daratumumab) for regular NHS funding in third line multiple myeloma, saying that gaps in clinical evidence mean cost-effectiveness data are unreliable.
